The University of Chicago Header Logo

Russell Z. Szmulewitz

TitleAssociate Professor
InstitutionUniversity of Chicago
DepartmentMedicine-Hematology and Oncology
AddressChicago IL 60637
Email
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Huang D, Lynch C, Serra LM, Sweis RF, Chang PJ, Stadler WM, Szmulewitz RZ, O'Donnell PH, Sidana A, Eggener SE, Shalhav AL, Liauw SL, Pitroda SP. Primary site stereotactic ablative body radiotherapy in localized, recurrent, and metastatic renal cell carcinoma. Clin Transl Radiat Oncol. 2024 Nov; 49:100879. PMID: 39529961; PMCID: PMC11551534.
      Citations:    
    2. Hussain M, Kocherginsky M, Agarwal N, Adra N, Zhang J, Paller CJ, Picus J, Reichert ZR, Szmulewitz RZ, Tagawa ST, Kuzel TM, Bazzi LA, Daignault-Newton S, Whang YE, Dreicer R, Stephenson RD, Rettig MB, Shevrin D, Gerke T, Chinnaiyan AM, Antonarakis ES, Hussain M, Kocherginsky M, Agarwal N, Adra N, Zhang J, Paller CJ, Picus J, Reichert ZR, Szmulewitz RZ, Tagawa ST, Kuzel TM, Bazzi LA, Daignault-Newton S, Whang YE, Dreicer R, Stephenson RD, Rettig MB, Shevrin D, Gerke T, Chinnaiyan AM, Antonarakis ES. Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway). Clin Cancer Res. 2024 Oct 01; 30(19):4318-4328. PMID: 39115414.
      Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
    3. Desai KB, Serritella AV, Stadler WM, O'Donnell PH, Sweis RF, Szmulewitz RZ. A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2024 Jun 03; 30(11):2384-2392. PMID: 38536082; PMCID: PMC11147727.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    4. Rajeev-Kumar G, Pitroda SP, Szmulewitz RZ, Skolarus T, Eggener SE, Liauw SL. Hormonal Therapy and Radiation Therapy in Prostate Cancer: 5-Year Outcomes From a Trial Evaluating Combined Androgen Blockade With 5-Alpha Reductase Inhibitors as an Alternative to Gonadotropin Releasing Hormone Agonists. Clin Genitourin Cancer. 2024 Aug; 22(4):102103. PMID: 38781786.
      Citations:    Fields:    Translation:Humans
    5. Bennett L, Jaiswal PK, Harkless RV, Long TM, Gao N, Vandenburg B, Selman P, Durdana I, Lastra RR, Vander Griend D, Adelaiye-Ogala R, Szmulewitz RZ, Conzen SD. Glucocorticoid Receptor (GR) Activation Is Associated with Increased cAMP/PKA Signaling in Castration-Resistant Prostate Cancer. Mol Cancer Ther. 2024 Apr 02; 23(4):552-563. PMID: 38030378; PMCID: PMC10985475.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    6. Schaeffer EM, Srinivas S, Adra N, An Y, Bitting R, Chapin B, Cheng HH, D'Amico AV, Desai N, Dorff T, Eastham JA, Farrington TA, Gao X, Gupta S, Guzzo T, Ippolito JE, Karnes RJ, Kuettel MR, Lang JM, Lotan T, McKay RR, Morgan T, Pow-Sang JM, Reiter R, Roach M, Robin T, Rosenfeld S, Shabsigh A, Spratt D, Szmulewitz R, Teply BA, Tward J, Valicenti R, Wong JK, Snedeker J, Freedman-Cass DA. NCCN Guidelines® Insights: Prostate Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024 04; 22(3):140-150. PMID: 38626801.
      Citations: 4     Fields:    Translation:Humans
    7. Halabi S, Guo S, Park JJ, Nanus DM, George DJ, Antonarakis ES, Danila DC, Szmulewitz RZ, McDonnell DP, Norris JD, Lu C, Luo J, Armstrong AJ. The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide. Clin Cancer Res. 2024 Mar 15; 30(6):1152-1159. PMID: 38236581; PMCID: PMC10947837.
      Citations: 3     Fields:    Translation:HumansCells
    8. Lynch C, Sweis RF, Modi P, Agarwal PK, Szmulewitz RZ, Stadler WM, O'Donnell PH, Liauw SL, Pitroda SP. Bladder-Preserving Trimodality Therapy With Capecitabine. Clin Genitourin Cancer. 2024 04; 22(2):476-482.e1. PMID: 38228414.
      Citations:    Fields:    Translation:Humans
    9. Gomez-Veiga F, Szmulewitz RZ, Holzbeierlein J, Azad AA, Iguchi T, Villers A, Alcaraz A, Alekseev B, Shore ND, Rosbrook B, Zohren F, Ma J, Haas GP, Stenzl A, Armstrong AJ. Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and =75 Years: ARCHES Post Hoc Analysis. Eur Urol Oncol. 2024 Aug; 7(4):860-869. PMID: 38072761.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    10. Meier JP, Zhang HJ, Freifelder R, Bhuiyan M, Selman P, Mendez M, Kankanamalage PHA, Brossard T, Pusateri A, Tsai HM, Leoni L, Penano S, Ghosh K, Broder BA, Markiewicz E, Renne A, Stadler W, Weichselbaum R, Nolen J, Kao CM, Chitneni SK, Rotsch DA, Szmulewitz RZ, Chen CT. Accelerator-Based Production of Scandium Radioisotopes for Applications in Prostate Cancer: Toward Building a Pipeline for Rapid Development of Novel Theranostics. Molecules. 2023 Aug 13; 28(16). PMID: 37630292; PMCID: PMC10458970.
      Citations: 2     Fields:    Translation:HumansAnimals
    11. Mir N, Curry G, Lee NK, Szmulewitz RZ, Huisingh-Scheetz M. A usability and participatory design study for GeRI, an open-source, remote cancer treatment toxicity and frailty monitoring platform for older adults. J Geriatr Oncol. 2024 01; 15(1):101595. PMID: 37487857; PMCID: PMC10800671.
      Citations: 1     Fields:    Translation:Humans
    12. Gupta S, Halabi S, Yang Q, Roy A, Tubbs A, Gore Y, George DJ, Nanus DM, Antonarakis ES, Danila DC, Szmulewitz RZ, Wenstrup R, Armstrong AJ. PSMA-positive Circulating Tumor Cell Detection and Outcomes with Abiraterone or Enzalutamide Treatment in Men with Metastatic Castrate-resistant Prostate Cancer. Clin Cancer Res. 2023 05 15; 29(10):1929-1937. PMID: 36897758; PMCID: PMC10192124.
      Citations: 7     Fields:    Translation:HumansCells
    13. Armstrong AJ, Iguchi T, Azad AA, Villers A, Alekseev B, Petrylak DP, Szmulewitz RZ, Alcaraz A, Shore ND, Holzbeierlein J, Rosbrook B, Zohren F, Haas GP, Gourgiotti G, El-Chaar N, Gomez-Veiga F, Stenzl A. The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES. Eur Urol. 2023 08; 84(2):229-241. PMID: 37179240.
      Citations: 2     Fields:    Translation:Humans
    14. Williams A, Gutgesell L, de Wet L, Selman P, Dey A, Avineni M, Kapoor I, Mendez M, Brown R, Lamperis S, Blajszczak C, Bueter E, Vander Griend DJ, Kregel S, Szmulewitz RZ. SOX2 expression in prostate cancer drives resistance to nuclear hormone receptor signaling inhibition through the WEE1/CDK1 signaling axis. Cancer Lett. 2023 07 01; 565:216209. PMID: 37169162.
      Citations: 4     Fields:    Translation:HumansCells
    15. Mir N, Burke O, Yates S, Rajasekaran T, Chan J, Szmulewitz R, Kanesvaran R. Androgen receptor pathway inhibitors, prostate cancer, and older adults: a global Young International Society of Geriatric Oncology drug review. Ther Adv Med Oncol. 2023; 15:17588359221149887. PMID: 36743522; PMCID: PMC9893362.
      Citations: 1     
    16. Quinn Z, Leiby B, Sonpavde G, Choudhury AD, Sweeney C, Einstein D, Szmulewitz R, Sartor O, Knudsen K, Yang ES, Kelly WK. Phase I Study of Niraparib in Combination with Radium-223 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer. Clin Cancer Res. 2023 01 04; 29(1):50-59. PMID: 36321991; PMCID: PMC9812873.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    17. Aggarwal R, Alumkal JJ, Szmulewitz RZ, Higano CS, Bryce AH, Lopez-Gitlitz A, McCarthy SA, Miladinovic B, McQuarrie K, Thomas S, Zhang K, Small EJ. Randomized, Open-Label Phase 2 Study of Apalutamide plus Androgen Deprivation Therapy versus Apalutamide Monotherapy versus Androgen Deprivation Monotherapy in Patients with Biochemically Recurrent Prostate Cancer. Prostate Cancer. 2022; 2022:5454727. PMID: 36212187; PMCID: PMC9534720.
      Citations:    
    18. Skolarus TA, Szmulewitz RZ. Editorial Comment. J Urol. 2022 11; 208(5):996. PMID: 36094862.
      Citations:    Fields:    
    19. Szmulewitz RZ, Petrylak D, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore ND, Gomez-Veiga F, Ivanescu C, Rosbrook B, Ramaswamy K, Ganguli A, Haas GP, Armstrong AJ, Stenzl A. The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups. Prostate. 2022 09; 82(13):1237-1247. PMID: 35675470.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    20. de Kouchkovsky I, Rao A, Carneiro BA, Zhang L, Lewis C, Phone A, Small EJ, Friedlander T, Fong L, Paris PL, Ryan CJ, Szmulewitz RZ, Aggarwal R. A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 04 14; 28(8):1531-1539. PMID: 35176163.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    21. Armstrong AJ, Azad AA, Iguchi T, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Alcaraz A, Alekseev B, Shore ND, Gomez-Veiga F, Rosbrook B, Zohren F, Yamada S, Haas GP, Stenzl A. Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2022 05 20; 40(15):1616-1622. PMID: 35420921; PMCID: PMC9113211.
      Citations: 62     Fields:    Translation:Humans
    22. Serritella AV, Shevrin D, Heath EI, Wade JL, Martinez E, Anderson A, Schonhoft J, Chu YL, Karrison T, Stadler WM, Szmulewitz RZ. Phase I/II Trial of Enzalutamide and Mifepristone, a Glucocorticoid Receptor Antagonist, for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2022 04 14; 28(8):1549-1559. PMID: 35110415; PMCID: PMC9012680.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    23. de Wet L, Williams A, Gillard M, Kregel S, Lamperis S, Gutgesell LC, Vellky JE, Brown R, Conger K, Paner GP, Wang H, Platz EA, De Marzo AM, Mu P, Coloff JL, Szmulewitz RZ, Vander Griend DJ. Correction to: SOX2 mediates metabolic reprogramming of prostate cancer cells. Oncogene. 2022 Feb; 41(8):1234. PMID: 35145235.
      Citations: 1     Fields:    
    24. de Wet L, Williams A, Gillard M, Kregel S, Lamperis S, Gutgesell LC, Vellky JE, Brown R, Conger K, Paner GP, Wang H, Platz EA, De Marzo AM, Mu P, Coloff JL, Szmulewitz RZ, Vander Griend DJ. SOX2 mediates metabolic reprogramming of prostate cancer cells. Oncogene. 2022 Feb; 41(8):1190-1202. PMID: 35067686; PMCID: PMC8858874.
      Citations: 22     Fields:    Translation:HumansCells
    25. Heiss BL, Geynisman DM, Martinez E, Wong ASC, Yong WP, Szmulewitz RZ, Stadler WM. Comparison of out-of-pocket costs and adherence between the two arms of the prospective, randomized abiraterone food effect trial. Support Care Cancer. 2022 Mar; 30(3):2803-2810. PMID: 34845502; PMCID: PMC8830594.
      Citations: 2     Fields:    Translation:Humans
    26. Azad AA, Armstrong AJ, Alcaraz A, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Alekseev B, Iguchi T, Shore ND, Gomez-Veiga F, Rosbrook B, Lee HJ, Haas GP, Stenzl A. Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk. Prostate Cancer Prostatic Dis. 2022 02; 25(2):274-282. PMID: 34420037.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    27. Pachynski RK, Morishima C, Szmulewitz R, Harshman L, Appleman L, Monk P, Bitting RL, Kucuk O, Millard F, Seigne JD, Fling SP, Maecker HT, Duault C, Ramchurren N, Hess B, D'Amico L, Lacroix A, Kaiser JC, Morre M, Cheever M, Yu EY, Fong L, Grégoire A. IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC). J Immunother Cancer. 2021 08; 9(8). PMID: 34452927; PMCID: PMC8404457.
      Citations: 25     Fields:    Translation:HumansCellsCTClinical Trials
    28. Szmulewitz RZ, Stadler WM, Ratain MJ. The Abiraterone Dosing Chess Match With Johnson & Johnson-Back in Check. JAMA Oncol. 2021 06 01; 7(6):827-828. PMID: 33662094.
      Citations:    Fields:    Translation:Humans
    29. Onderdonk BE, Dorn PL, Martinez C, Arif F, Cloutier D, Antic T, Golden DW, Karrison T, Pitroda SP, Szmulewitz RZ, Liauw SL. A prospective clinical and transcriptomic feasibility study of oral-only hormonal therapy with radiation for unfavorable prostate cancer in men 70 years of age and older or with comorbidity. Cancer. 2021 08 01; 127(15):2631-2640. PMID: 33882144.
      Citations: 3     Fields:    Translation:HumansCells
    30. Scher HI, Armstrong AJ, Schonhoft JD, Gill A, Zhao JL, Barnett E, Carbone E, Lu J, Antonarakis ES, Luo J, Tagawa S, Dos Anjos CH, Yang Q, George D, Szmulewitz R, Danila DC, Wenstrup R, Gonen M, Halabi S. Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer. Eur J Cancer. 2021 06; 150:83-94. PMID: 33894633; PMCID: PMC8772024.
      Citations: 24     Fields:    Translation:HumansCells
    31. Brown LC, Halabi S, Schonhoft JD, Yang Q, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Barnett ES, Carbone EA, Zhao JL, Healy P, Anand M, Gill A, Jendrisak A, Berry WR, Gupta S, Gregory SG, Wenstrup R, Antonarakis ES, George DJ, Scher HI, Armstrong AJ. Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide. Clin Cancer Res. 2021 07 15; 27(14):4077-4088. PMID: 33820782; PMCID: PMC8282682.
      Citations: 16     Fields:    Translation:HumansCells
    32. Armstrong AJ, Shore ND, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Gomez-Veiga F, Rosbrook B, Lee HJ, Haas GP, Stenzl A. Reply by Authors. J Urol. 2021 05; 205(5):1371. PMID: 33705222.
      Citations:    Fields:    
    33. Denmeade SR, Wang H, Agarwal N, Smith DC, Schweizer MT, Stein MN, Assikis V, Twardowski PW, Flaig TW, Szmulewitz RZ, Holzbeierlein JM, Hauke RJ, Sonpavde G, Garcia JA, Hussain A, Sartor O, Mao S, Cao H, Fu W, Wang T, Abdallah R, Lim SJ, Bolejack V, Paller CJ, Carducci MA, Markowski MC, Eisenberger MA, Antonarakis ES. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. J Clin Oncol. 2021 04 20; 39(12):1371-1382. PMID: 33617303; PMCID: PMC8274807.
      Citations: 41     Fields:    Translation:HumansCTClinical Trials
    34. Lee RT, Kwon N, Wu J, To C, To S, Szmulewitz R, Tchekmedyian R, Holmes HM, Olopade OI, Stadler WM, Von Roenn J. Prevalence of potential interactions of medications, including herbs and supplements, before, during, and after chemotherapy in patients with breast and prostate cancer. Cancer. 2021 06 01; 127(11):1827-1835. PMID: 33524183.
      Citations: 17     Fields:    Translation:Humans
    35. Armstrong AJ, Shore ND, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Gomez-Veiga F, Rosbrook B, Lee HJ, Haas GP, Stenzl A. Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses. J Urol. 2021 May; 205(5):1361-1371. PMID: 33356529.
      Citations: 15     Fields:    Translation:HumansCTClinical Trials
    36. Villers A, Shore N, Armstrong A, Szmulewitz R, Petrylak D, Holzbeierlein J, Azad A, Alcaraz A, Alekseev B, Iguchi T, Gomez-Veiga F, Rosbrook B, Lee H, Haas G, Stenzl A. Prog Urol. 2020 Nov; 30(13):745. PMID: 33157657.
      Citations:    
    37. Armstrong AJ, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Healy P, Anand M, Berry WR, Zhang T, Harrison MR, Lu C, Chen Y, Galletti G, Schonhoft JD, Scher HI, Wenstrup R, Tagawa ST, Antonarakis ES, George DJ, Halabi S. Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer. JCO Precis Oncol. 2020; 4. PMID: 33154984; PMCID: PMC7608579.
      Citations: 38     Fields:    
    38. Eastham JA, Heller G, Halabi S, Monk JP, Beltran H, Gleave M, Evans CP, Clinton SK, Szmulewitz RZ, Coleman J, Hillman DW, Watt CR, George S, Sanda MG, Hahn OM, Taplin ME, Parsons JK, Mohler JL, Small EJ, Morris MJ. Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. J Clin Oncol. 2020 09 10; 38(26):3042-3050. PMID: 32706639; PMCID: PMC7479762.
      Citations: 36     Fields:    Translation:Humans
    39. Cheong EJY, Nair PC, Neo RWY, Tu HT, Lin F, Chiong E, Esuvaranathan K, Fan H, Szmulewitz RZ, Peer CJ, Figg WD, Chai CLL, Miners JO, Chan ECY. Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen. J Pharmacol Exp Ther. 2020 09; 374(3):438-451. PMID: 32554434; PMCID: PMC7469252.
      Citations: 10     Fields:    Translation:HumansCells
    40. Dunshee C, De Giorgi U, Alekseev B, Iguchi T, Szmulewitz RZ, Flaig TW, Tombal B, Morlock R, Ivanescu C, Ramaswamy K, Armstrong AJ, Stenzl A, Saad F. Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study. Eur Urol. 2020 10; 78(4):603-614. PMID: 32336645.
      Citations: 17     Fields:    Translation:HumansCTClinical Trials
    41. Danila DC, Szmulewitz RZ, Vaishampayan U, Higano CS, Baron AD, Gilbert HN, Brunstein F, Milojic-Blair M, Wang B, Kabbarah O, Mamounas M, Fine BM, Maslyar DJ, Ungewickell A, Scher HI. Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2019 12 20; 37(36):3518-3527. PMID: 31689155; PMCID: PMC7351321.
      Citations: 37     Fields:    Translation:HumansCTClinical Trials
    42. Falchook G, Rosen S, LoRusso P, Watts J, Gupta S, Coombs CC, Talpaz M, Kurzrock R, Mita M, Cassaday R, Harb W, Peguero J, Smith DC, Piha-Paul SA, Szmulewitz R, Noel MS, Yeleswaram S, Liu P, Switzky J, Zhou G, Zheng F, Mehta A. Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. Clin Cancer Res. 2020 03 15; 26(6):1247-1257. PMID: 31527168; PMCID: PMC7528620.
      Citations: 36     Fields:    Translation:HumansCTClinical Trials
    43. George DJ, Halabi S, Healy P, Barak I, Winters C, Anand M, Wilder R, Klein M, Martinez E, Nixon AB, Harrison MR, Szmulewitz R, Armstrong AJ. Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. Prostate. 2019 11; 79(15):1752-1761. PMID: 31497882.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    44. Piha-Paul SA, Sachdev JC, Barve M, LoRusso P, Szmulewitz R, Patel SP, Lara PN, Chen X, Hu B, Freise KJ, Modi D, Sood A, Hutti JE, Wolff J, O'Neil BH. First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors. Clin Cancer Res. 2019 11 01; 25(21):6309-6319. PMID: 31420359.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    45. Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore ND, Rosbrook B, Sugg J, Baron B, Chen L, Stenzl A. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2019 11 10; 37(32):2974-2986. PMID: 31329516; PMCID: PMC6839905.
      Citations: 363     Fields:    Translation:HumansCTClinical Trials
    46. Michaelson MD, Gupta S, Agarwal N, Szmulewitz R, Powles T, Pili R, Bruce JY, Vaishampayan U, Larkin J, Rosbrook B, Wang E, Murphy D, Wang P, Valota O, Shepard DR, Lechuga MJ. A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors. Oncologist. 2019 09; 24(9):1151-e817. PMID: 31171735; PMCID: PMC6738313.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    47. Armstrong AJ, Halabi S, Luo J, Nanus DM, Giannakakou P, Szmulewitz RZ, Danila DC, Healy P, Anand M, Rothwell CJ, Rasmussen J, Thornburg B, Berry WR, Wilder RS, Lu C, Chen Y, Silberstein JL, Kemeny G, Galletti G, Somarelli JA, Gupta S, Gregory SG, Scher HI, Dittamore R, Tagawa ST, Antonarakis ES, George DJ. Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. J Clin Oncol. 2019 05 01; 37(13):1120-1129. PMID: 30865549; PMCID: PMC6494355.
      Citations: 165     Fields:    Translation:HumansCellsCTClinical Trials
    48. Leng J, Akthar AS, Szmulewitz RZ, O'Donnell PH, Sweis RF, Pitroda SP, Smith N, Steinberg GD, Liauw SL. Safety and Efficacy of Hypofractionated Radiotherapy With Capecitabine in Elderly Patients With Urothelial Carcinoma. Clin Genitourin Cancer. 2019 Feb; 17(1):e12-e18. PMID: 30392939.
      Citations: 2     Fields:    Translation:Humans
    49. Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J, Mosquera JM, Sailer V, Bareja R, Romanel A, Gumpeni N, Sboner A, Dardenne E, Puca L, Prandi D, Rubin MA, Scher HI, Rickman DS, Demichelis F, Nanus DM, Ballman KV, Tagawa ST. A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clin Cancer Res. 2019 01 01; 25(1):43-51. PMID: 30232224; PMCID: PMC6320304.
      Citations: 126     Fields:    Translation:HumansCellsCTClinical Trials
    50. Szmulewitz RZ, Karrison T, Stadler WM, Ratain MJ. Low-Dose Abiraterone With Food: Rebutting an Editorial. J Clin Oncol. 2018 10 20; 36(30):3060-3061. PMID: 30188785.
      Citations: 3     Fields:    Translation:Humans
    51. Szmulewitz RZ, Stadler WM, Ratain MJ. Reply to I.F. Tannock, P. Isaacsson Velho et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al. J Clin Oncol. 2018 10 20; 36(30):3064-3065. PMID: 30188784.
      Citations:    Fields:    Translation:Humans
    52. Monk P, Liu G, Stadler WM, Geyer S, Huang Y, Wright J, Villalona-Calero M, Wade J, Szmulewitz R, Gupta S, Mortazavi A, Dreicer R, Pili R, Dawson N, George S, Garcia JA. Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Invest New Drugs. 2018 10; 36(5):919-926. PMID: 30083962; PMCID: PMC6153554.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    53. Bhanvadia RR, VanOpstall C, Brechka H, Barashi NS, Gillard M, McAuley EM, Vasquez JM, Paner G, Chan WC, Andrade J, De Marzo AM, Han M, Szmulewitz RZ, Vander Griend DJ. MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res. 2018 08 01; 24(15):3668-3680. PMID: 29716922; PMCID: PMC6082699.
      Citations: 41     Fields:    Translation:HumansCells
    54. Sweis RF, Zha Y, Pass L, Heiss B, Chongsuwat T, Luke JJ, Gajewski TF, Szmulewitz R. Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. J Immunother Cancer. 2018 04 04; 6(1):24. PMID: 29618376; PMCID: PMC5883337.
      Citations: 7     Fields:    Translation:HumansCells
    55. Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, Harvey RD, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, Stadler WM, Ratain MJ. Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol. 2018 05 10; 36(14):1389-1395. PMID: 29590007; PMCID: PMC5941614.
      Citations: 56     Fields:    Translation:HumansCTClinical Trials
    56. Kach J, Long TM, Selman P, Tonsing-Carter EY, Bacalao MA, Lastra RR, de Wet L, Comiskey S, Gillard M, VanOpstall C, West DC, Chan WC, Griend DV, Conzen SD, Szmulewitz RZ. Selective Glucocorticoid Receptor Modulators (SGRMs) Delay Castrate-Resistant Prostate Cancer Growth. Mol Cancer Ther. 2017 08; 16(8):1680-1692. PMID: 28428441; PMCID: PMC5544558.
      Citations: 25     Fields:    Translation:HumansAnimalsCells
    57. Armstrong AJ, Humeniuk MS, Healy P, Szmulewitz R, Winters C, Kephart J, Harrison MR, Martinez E, Mundy K, Halabi S, George D. Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial. Prostate. 2017 03; 77(4):385-395. PMID: 27862097; PMCID: PMC6309626.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    58. Sweis RF, Medved M, Towey S, Karczmar GS, Oto A, Szmulewitz RZ, O'Donnell PH, Fishkin P, Karrison T, Stadler WM. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clin Genitourin Cancer. 2017 04; 15(2):207-212. PMID: 27634566; PMCID: PMC5315677.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    59. Kregel S, Chen JL, Tom W, Krishnan V, Kach J, Brechka H, Fessenden TB, Isikbay M, Paner GP, Szmulewitz RZ, Vander Griend DJ. Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer. Oncotarget. 2016 May 03; 7(18):26259-74. PMID: 27036029; PMCID: PMC5041979.
      Citations: 64     Fields:    Translation:HumansAnimalsCells
    60. Posadas EM, Ahmed RS, Karrison T, Szmulewitz RZ, O'Donnell PH, Wade JL, Shen J, Gururajan M, Sievert M, Stadler WM. Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study. Prostate. 2016 Feb 15; 76(3):286-93. PMID: 26493492; PMCID: PMC4904773.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    61. Kach J, Conzen SD, Szmulewitz RZ. Targeting the glucocorticoid receptor in breast and prostate cancers. Sci Transl Med. 2015 Sep 16; 7(305):305ps19. PMID: 26378243; PMCID: PMC4807967.
      Citations: 38     Fields:    Translation:HumansAnimalsCells
    62. Reyes EE, Gillard M, Duggan R, Wroblewski K, Kregel S, Isikbay M, Kach J, Brechka H, Weele DJ, Szmulewitz RZ, Griend DJ. Molecular analysis of CD133-positive circulating tumor cells from patients with metastatic castration-resistant prostate cancer. J Transl Sci. 2015 Jul; 1(1). PMID: 26753099; PMCID: PMC4704802.
      Citations: 10     
    63. VanderWeele DJ, Paner GP, Fleming GF, Szmulewitz RZ. Sustained Complete Response to Cytotoxic Therapy and the PARP Inhibitor Veliparib in Metastatic Castration-Resistant Prostate Cancer - A Case Report. Front Oncol. 2015; 5:169. PMID: 26258074; PMCID: PMC4510409.
      Citations: 9     
    64. Reyes EE, VanderWeele DJ, Isikbay M, Duggan R, Campanile A, Stadler WM, Vander Griend DJ, Szmulewitz RZ. Quantitative characterization of androgen receptor protein expression and cellular localization in circulating tumor cells from patients with metastatic castration-resistant prostate cancer. J Transl Med. 2014 Nov 26; 12:313. PMID: 25424879; PMCID: PMC4252013.
      Citations: 26     Fields:    Translation:HumansCells
    65. Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, Morse A, Szmulewitz RZ, Friedlander TW, Fong L, Lin AM, Harzstark AL, Molina A, Small EJ, Ryan CJ. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res. 2014 Dec 15; 20(24):6269-76. PMID: 25336698; PMCID: PMC4277885.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    66. Kregel S, Szmulewitz RZ, Vander Griend DJ. The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells. Prostate. 2014 Nov; 74(15):1530-43. PMID: 25175748; PMCID: PMC4174985.
      Citations: 13     Fields:    Translation:HumansCells
    67. Geynisman DM, Szmulewitz RZ, Plimack ER. Corticosteroids and prostate cancer: friend or foe? Eur Urol. 2015 May; 67(5):874-5. PMID: 25151018.
      Citations: 2     Fields:    Translation:Humans
    68. Cohen A, Richards KA, Patel S, Weiner A, Eggener SE, Szmulewitz RZ. Metastatic small cell carcinoma of the prostate: Population-based analysis of patient characteristics and treatment paradigms. Urol Oncol. 2015 Feb; 33(2):70.e1-7. PMID: 25044254.
      Citations: 5     Fields:    Translation:Humans
    69. Weiner AB, Patel SG, Richards KA, Szmulewitz RZ, Eggener SE. Population-based analysis of treatment modalities and survival for clinically localized small-cell carcinoma of the prostate. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):286-91. PMID: 25027862.
      Citations: 4     Fields:    Translation:HumansPHPublic Health
    70. Szmulewitz RZ, Ratain MJ. Vemurafenib oral bioavailability: an insoluble problem. J Clin Pharmacol. 2014 Apr; 54(4):375-7. PMID: 24757719.
      Citations: 2     Fields:    Translation:Humans
    71. Isikbay M, Otto K, Kregel S, Kach J, Cai Y, Vander Griend DJ, Conzen SD, Szmulewitz RZ. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer. Horm Cancer. 2014 Apr; 5(2):72-89. PMID: 24615402; PMCID: PMC4440041.
      Citations: 144     Fields:    Translation:HumansAnimalsCells
    72. Drazer MW, Prasad SM, Huo D, Schonberg MA, Dale W, Szmulewitz RZ, Eggener SE. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making. Cancer. 2014 May 15; 120(10):1491-8. PMID: 24523016.
      Citations: 35     Fields:    Translation:HumansPHPublic Health
    73. Kregel S, Kiriluk KJ, Rosen AM, Cai Y, Reyes EE, Otto KB, Tom W, Paner GP, Szmulewitz RZ, Vander Griend DJ. Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer. PLoS One. 2013; 8(1):e53701. PMID: 23326489; PMCID: PMC3543364.
      Citations: 88     Fields:    Translation:HumansAnimalsCells
    74. Szmulewitz RZ, Ratain MJ. Playing Russian roulette with tyrosine kinase inhibitors. Clin Pharmacol Ther. 2013 Mar; 93(3):242-4. PMID: 23340477.
      Citations: 8     Fields:    Translation:Humans
    75. Geynisman DM, Szmulewitz RZ, Stadler WM. A trial postmortem: challenges in conducting a randomized, double-blind, phase 2 study in men with castration-resistant prostate cancer. Eur Urol. 2012 Nov; 62(5):864-6. PMID: 22939385.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    76. Ward JE, Karrison T, Chatta G, Hussain M, Shevrin D, Szmulewitz RZ, O'Donnell PH, Stadler WM, Posadas EM. A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study. Prostate Cancer Prostatic Dis. 2012 Mar; 15(1):87-92. PMID: 22006050; PMCID: PMC4312616.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    77. Szmulewitz RZ, Chung E, Al-Ahmadie H, Daniel S, Kocherginsky M, Razmaria A, Zagaja GP, Brendler CB, Stadler WM, Conzen SD. Serum/glucocorticoid-regulated kinase 1 expression in primary human prostate cancers. Prostate. 2012 Feb 01; 72(2):157-64. PMID: 21563193; PMCID: PMC6000822.
      Citations: 35     Fields:    Translation:Humans
    78. Shoushtari AN, Szmulewitz RZ, Rinker-Schaeffer CW. Metastasis-suppressor genes in clinical practice: lost in translation? Nat Rev Clin Oncol. 2011 Jun; 8(6):333-42. PMID: 21522123.
      Citations: 25     Fields:    Translation:HumansCells
    79. Szmulewitz RZ, Clark R, Lotan T, Otto K, Taylor Veneris J, Macleod K, Rinker-Schaeffer C. MKK4 suppresses metastatic colonization by multiple highly metastatic prostate cancer cell lines through a transient impairment in cell cycle progression. Int J Cancer. 2012 Feb 01; 130(3):509-20. PMID: 21351092; PMCID: PMC3465713.
      Citations: 9     Fields:    Translation:AnimalsCells
    80. Sajid S, Mohile SG, Szmulewitz R, Posadas E, Dale W. Individualized decision-making for older men with prostate cancer: balancing cancer control with treatment consequences across the clinical spectrum. Semin Oncol. 2011 Apr; 38(2):309-25. PMID: 21421119.
      Citations: 11     Fields:    Translation:Humans
    81. Jayram G, Szmulewitz RZ, Eggener SE. Management of good-risk metastatic nonseminomatous germ cell tumors of the testis: current concepts and controversies. Indian J Urol. 2010 Jan-Mar; 26(1):92-7. PMID: 20535293; PMCID: PMC2878446.
      Citations: 1     
    82. Szmulewitz R, Mohile S, Posadas E, Kunnavakkam R, Karrison T, Manchen E, Stadler WM. A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol. 2009 Jul; 56(1):97-103. PMID: 19282098; PMCID: PMC2885777.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    83. Taylor JL, Szmulewitz RZ, Lotan T, Hickson J, Griend DV, Yamada SD, Macleod K, Rinker-Schaeffer CW. New paradigms for the function of JNKK1/MKK4 in controlling growth of disseminated cancer cells. Cancer Lett. 2008 Dec 08; 272(1):12-22. PMID: 18572308.
      Citations: 16     Fields:    Translation:Humans
    84. Stadler WM, Szmulewitz RZ. Sunitinib--a new standard of care for metastatic renal cell carcinoma. Nat Clin Pract Oncol. 2007 Aug; 4(8):458-9. PMID: 17593923.
      Citations: 2     Fields:    
    85. Szmulewitz RZ, Chang RY, Blank SV, Curtin JP, Hochster HS, Hamilton AL, Hornreich G, Muggia FM. Sequential phase II studies for endometrial cancer (EC): Pegylated liposomal doxorubicin (LD) with either paclitaxel (P) or docetaxel (D). J Clin Oncol. 2005 Jun; 23(16_suppl):5134. PMID: 27946680.
      Citations:    
    86. Anselmo J, Kay T, Dennis K, Szmulewitz R, Refetoff S, Weiss RE. Resistance to thyroid hormone does not abrogate the transient thyrotoxicosis associated with gestation: report of a case. J Clin Endocrinol Metab. 2001 Sep; 86(9):4273-5. PMID: 11549661.
      Citations: 5     Fields:    Translation:Humans
    Szmulewitz's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (296)
    Explore
    _
    Co-Authors (41)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _